Clinical Trial Identifies Common Antidepressant Fluvoxamine as Breakthrough Treatment for Chronic Fatigue in Long COVID Patients

McMaster University study finds common antidepressant fluvoxamine significantly eases long COVID fatigue, offering a low-cost treatment for millions.

By: AXL Media

Published: Mar 31, 2026, 3:37 AM EDT

Source: Information for this report was sourced from McMaster University

A Vital Breakthrough for Persistent Viral Exhaustion

The search for effective medical interventions for long COVID has reached a significant milestone with the identification of a widely available pharmaceutical solution. Researchers from a coalition of international universities have demonstrated that fluvoxamine, an antidepressant typically used for obsessive-compulsive disorder, provides meaningful relief from the profound fatigue associated with post-viral syndrome. This discovery offers the first evidence-based hope for millions of individuals who have remained unable to return to their normal professional or personal lives years after their initial infection. According to Edward Mills of McMaster University, the clinical potential is immense because the drug is already well-understood by the medical community.

The Failure of Traditional Diabetes Medication in Recovery

While the study focused on repurposing existing drugs, it also served to narrow the scope of effective treatments by ruling out other common medications. The clinical trial specifically tested metformin, a standard treatment for diabetes, which had previously shown promise in preventing long COVID if administered during an active infection. However, the data revealed that once long COVID symptoms are established, metformin offers no meaningful benefit in alleviating fatigue. This distinction is crucial for clinicians who must now pivot away from metabolic regulators toward the neurological or inflammatory pathways targeted by fluvoxamine.

Sophisticated Trial Design Accelerates Medical Evidence

The research utilized a Bayesian adaptive design, a cutting-edge statistical approach that allows a trial to be modified or stopped as soon as the results reach a threshold of certainty. This method proved instrumental in the REVIVE-TOGETHER trial, as it allowed the team to reach definitive conclusions more rapidly than traditional, rigid study formats would permit. By stopping the treatment arms early when the evidence became clear, the researchers were able to generate actionable data without unnecessary delays. Gilmar Reis, the study’s lead author, noted that this innovation in trial design is as significant as the medical findings themselves in the race to treat global health crises.